An interventional study of Standard of care physical therapy and Shoulder pacemaker with physical therapy in Shoulder Injuries, sponsored by University of Utah. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by University of Utah · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Shoulder Injuries with a site in United States — 14 open to participants now, 18 under way, none of them phase 3. Shoulder Injuries · United States.
Among the 39 studies in Shoulder Injuries with a site in United States, this one is the 6th largest by planned enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2023, is one of 20 with no phase, reaches primary completion later than 8 of the 17 other live ones, and was the 34th registered.
118 studies on the registry are indexed under Shoulder Injuries; 32 are open to participants now.
Browse Shoulder Injuries studies →14 of the 39 studies in Shoulder Injuries with a site in United States are open now. Recruiting first, the newest first:
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
Stryker Endoscopy · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18–95 · Healthy volunteers
Duke University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Shoulder Injuries studies recruiting now, 8 (47%) set no upper age limit and 6 (35%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 55 across 69 interventional studies indexed under Shoulder Injuries.
Median enrollment 64 across the 26 interventional studies, 59 across the 13 observational. Of the 20 that completed or were terminated, 5 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 39 have an industry lead sponsor. The 10 most frequent:
University of Utah is the lead sponsor of 997 studies on the registry; 176 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
University of Utah has 1 study filed under Shoulder Injuries — fewer than ten, so there is no comparison to draw.
7 of the studies in Shoulder Injuries with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06016257Cedars-Sinai Medical CenterUsing VirtuaCareTM Platform for Home Programs in Acute and Chronic Shoulder Conditions: A Pilot Study | 2026-12-31 |
| NCT04109638Stanford UniversityPulsed Electromagnetic Field (PEMF) Therapy for Post-operative Pain Following Orthopedic Surgery | 2027-02 |
| NCT05344898University of Maryland, BaltimoreSubscap Reverse Shoulder Arthroplasty | 2027-05-15 |
| NCT02600910The University of Texas Medical Branch, GalvestonNatural History of Shoulder Pathology in Manual Wheelchair Users | 2027-06 |
| NCT06501859University of UtahRehabilitation With the Shoulder Pacemaker | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 39 studies in Shoulder Injuries with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators purpose of the proposed study is to use the FDA approved Shoulder Pacemaker device in patients undergoing reverse shoulder arthroplasty and study the functional outcomes compared to a standard post-operative rehabilitation program. The investigators hypothesize that use of the Shoulder Pacemaker reduce pain and will allow for improved range of motion and function in patients undergoing RSA. The findings of this research may very well improve function in RSA patients through a novel, non-invasive approach.
The reverse shoulder arthroplasty (RSA) has increased utility in recent years for shoulder conditions such as rotator cuff tear arthropathy, massive irreparable rotator cuff tears, severe glenohumeral arthritis, proximal humerus fracture, and failed shoulder arthroplasty. While RSA may commonly be the only surgical treatment for some of these conditions, the outcomes and adverse event profiles are significant. Specifically, RSA patients often complain of poor range of motion and function with the arm above the head. Despite many attempts at solving these shortcomings with new implant design iterations and improved implant positioning, these continue to be a source of frustration with patients and surgeons alike.
Poor scapulothoracic motion is associated with poor shoulder range of motion, especially after RSA. Past investigators have shown that in certain RSA patients, there is a near complete loss of glenohumeral motion and forward elevation and abduction is highly dependent on scapulothoracic motion. In a separate study, In addition, these investigators demonstrated that internal rotation after RSA is largely dependent on scapulothoracic motion. Several years ago, a device called the Shoulder Pacemaker (Alyve Medical, Denver, CO) was developed initially for the treatment of functional instability in the setting of scapular dyskinesis. It functions as a wearable muscle electrostimulator that allows for periscapular muscle stimulation as well as feedback on shoulder range of motion. The motion technology recognizes muscle movement and automatically sets the appropriate stimulation intensity according to the movement. This improves scapular muscle recruitment during range of motion. While the data is limited, there has been some early promising results for this pathology. As function after RSA is particularly reliant on scapulothoracic function, the current investigators may infer that use of the Shoulder Pacemaker device may function well in patients with reverse shoulder replacements. Specifically, the device would allow patients to train their periscapular musculature after RSA to improve global shoulder motion and function. To the current investigators knowledge, there is no current research on the use of the Shoulder Pacemaker after RSA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Control group and will not use the shoulder pacemaker, but will participate in a standardized physical therapy protocol for 3 months.
Other: Standard of care physical therapy
Include a standardized physical therapy protocol with utilization of the Shoulder Pacemaker device 3 times per week over a 3-month period starting at 6 weeks post-operatively.
Device: Shoulder pacemaker with physical therapy
Standard rehabilitation protocol for 3 months.
Standardized rehabilitation protocol with utilization of the shoulder pacemaker device 3 times per week over a 3-month period.
American Shoulder and Elbow Surgeons score
Shoulder specific scoring system out of 100. A patient-reported score with visual analog scale for pain and functional subscales ranging from 0 (worse pain and function loss) to 50 (no pain and excellent function). Both scores are summed for a maximum score of 100.
Time frame: Pre-operatively
American Shoulder and Elbow Surgeons score
Shoulder specific scoring system out of 100. A patient-reported score with visual analog scale for pain and functional subscales ranging from 0 (worse pain and function loss) to 50 (no pain and excellent function). Both scores are summed for a maximum score of 100.
Time frame: 6 weeks after surgery
American Shoulder and Elbow Surgeons score
Shoulder specific scoring system out of 100. A patient-reported score with visual analog scale for pain and functional subscales ranging from 0 (worse pain and function loss) to 50 (no pain and excellent function). Both scores are summed for a maximum score of 100.
Time frame: 3 months after surgery
American Shoulder and Elbow Surgeons score
Shoulder specific scoring system out of 100. A patient-reported score with visual analog scale for pain and functional subscales ranging from 0 (worse pain and function loss) to 50 (no pain and excellent function). Both scores are summed for a maximum score of 100.
Time frame: 6 months after surgery
American Shoulder and Elbow Surgeons score
Shoulder specific scoring system out of 100. A patient-reported score with visual analog scale for pain and functional subscales ranging from 0 (worse pain and function loss) to 50 (no pain and excellent function). Both scores are summed for a maximum score of 100.
Time frame: 1 year after surgery
Started Aug 2023 (actual). Primary completion is estimated for Jul 2027, 47 months after the start.
Of 38 non-industry interventional studies with no phase under Shoulder Injuries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 45. This study's planned 47 months is above that.
Counting every sponsor, half of 43 studies reached it within 15 months; a quarter within 7 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.